Inclusion Criteria:

          -  Patients must have histologic diagnosis of epithelial ovarian, fallopian tube, or
             primary peritoneal carcinoma per pre-treatment biopsies by laparoscopy, or
             interventional radiology or CT guided core biopsy.

          -  Patients with the following histologic epithelial cell types are eligible: High grade
             serous adenocarcinoma, endometrioid adenocarcinoma, undifferentiated carcinoma, clear
             cell adenocarcinoma, mixed epithelial carcinoma, or adenocarcinoma not otherwise
             specified (N.O.S.).

          -  Adequate bone marrow function, renal function, hepatic function, and neurologic
             function per protocol.

          -  Patients should be free of active infection requiring parenteral antibiotics or a
             serious uncontrolled medical illness or disorder within four weeks of study entry.

          -  Any hormonal therapy directed at the malignant tumor must be discontinued at least one
             week prior to registration. Continuation of hormone replacement therapy is permitted.

          -  Patients must have a performance status score of 0, 1, or 2 by Eastern Cooperative
             Group (ECOG) criteria.

          -  Patients of childbearing potential must have a negative pregnancy test prior to the
             study entry and be practicing an effective form of contraception. If applicable,
             patients must discontinue breastfeeding prior to study entry.

          -  Patients must have satisfactory results for the baseline laboratory analyses and
             diagnostic procedures as specified in the protocol.

          -  Patients must have pre-treatment tumor tissue available or agree for tissue collection
             from IR guided biopsy.

          -  Life expectancy of at least 3 months

        Exclusion Criteria:

          -  Prior treatment with PTC596 or standard of care drugs (cis- or carboplatin or
             paclitaxel.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to PTC596 or other agents used in this study.

          -  Have a clinical requirement for ongoing systemic immunosuppressive therapy such as
             chronic steroid use not related to chemotherapy administration.

          -  Receiving treatment for active autoimmune disease.

          -  History of other invasive malignancies, with the exception of non-melanoma skin cancer
             and other specific malignancies within the last three years.

          -  Prior radiotherapy to any portion of the abdominal cavity or pelvis.

          -  Prior chemotherapy for any abdominal or pelvic tumor.

          -  Known active hepatitis, ongoing systemic bacterial, fungal, or viral infection; known
             human immunodeficiency virus (HIV) infection or acquired-immunodeficiency syndrome
             (AIDS)-related illness.

          -  Have concurrent severe medical problems unrelated to the malignancy that would
             significantly limit full compliance with the study.

          -  Have childbearing potential but not practicing adequate contraception.

          -  History or active CNS disease.

          -  Concomitant therapy with any of the following: other non-study cytotoxic chemotherapy;
             other investigational therapies.

          -  Prior bone marrow/hematopoietic stem cell transplantation

          -  History of solid organ, bone marrow, or progenitor cell transplantation

          -  History of major surgical procedure within 28 days prior to start of study treatment

          -  Presence or history of moderate to severe pulmonary dysfunction.

          -  Use of an investigational drug within 4 weeks of dosing in the current study